CN100377723C - Application of fleece flower root in preparing medicine for treating fatty liver - Google Patents
Application of fleece flower root in preparing medicine for treating fatty liver Download PDFInfo
- Publication number
- CN100377723C CN100377723C CNB2004100295663A CN200410029566A CN100377723C CN 100377723 C CN100377723 C CN 100377723C CN B2004100295663 A CNB2004100295663 A CN B2004100295663A CN 200410029566 A CN200410029566 A CN 200410029566A CN 100377723 C CN100377723 C CN 100377723C
- Authority
- CN
- China
- Prior art keywords
- polygoni multiflori
- radix polygoni
- crude extract
- glucoside
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a preparation method of a Chinese medicine fleeceflower preparation, which comprises the following steps: fleeceflower is crushed and prepared into powder; the powder is extracted, concentrated, separated and dried; then, crude extracts of fleeceflower glycoside are obtained, and then, the crude extracts are prepared into oral preparations. The preparation method can be applied to the processes of preparing medicines for treating adiposis hepatica.
Description
Technical field
The present invention relates to the preparation method of the Radix Polygoni Multiflori, mainly relate to treat the preparation method of fatty liver medicine.
Background technology
The Radix Polygoni Multiflori is the Chinese medicine material, has loosening bowel to relieve constipation, invigorating the liver and kidney, benefiting essence-blood, black beard and hair, bone and muscle strengthening.Be used for diseases such as dryness of the intestine constipation, blood deficiency and yellow complexion, vertigo and tinnitus, early whitening of beard and hair, soreness of the waist and knees, numb limbs and tense tendons and hyperlipemia, and be used for multiple recurrence preparation and decoction.At present still do not have the Radix Polygoni Multiflori preparation that single Radix Polygoni Multiflori medical material is made, more do not have treatment fatty liver curative effect of medication.Adopt the Radix Polygoni Multiflori preparation of this technology preparation, have the curative effect of treatment fatty liver.
Summary of the invention
The objective of the invention is to adopt the formulation method of new system, prepare a kind of medicine that can be used for treating fatty liver.In order to solve the problems of the technologies described above, the present invention is achieved through the following technical solutions:
Radix Polygoni Multiflori preparation is prepared from by Radix Polygoni Multiflori glucoside crude extract and other adjuvants.Wherein Radix Polygoni Multiflori medical material is ground into coarse powder (by 8～20 orders) earlier before feeding intake; Radix Polygoni Multiflori glucoside crude extract preparation process is as follows:
1) Radix Polygoni Multiflori medicinal material coarse powder adds 30%-70% ethanol 6-10 and doubly measures, and backflow 0.5-1 hour, filters; The 30%-70% ethanol 6-8 that redoublings for the second time doubly measures, and backflow 0.5-1 hour, merge backflow, filter, get filtrate;
2) get filtrate recycling ethanol after, decompression (temperature is 55～70 ℃, and vacuum is 0.07～0.09Mpa) to concentrate, concentrated solution 1, it is that 0.25～0.50g/ml or relative density are 1.01～1.06 that concentrated solution 1 contains the crude drug amount;
3) get concentrated solution 1 usefulness macroporous resin and separate, obtain eluent; Described macroporous resin is D
101, DM
301, HPD
100One of type resin column is used the 20%-70% ethanol elution;
4) eluent reclaims ethanol to there not being the alcohol flavor, and concentrate concentrated solution 2; Described recovery ethanol and concentration process are decompression to carry out, and 55～70 ℃ of temperature, vacuum are 0.07～0.09Mpa, and it is that 1.5～2.5g/ml or relative density are 1.05～1.25 that concentrated solution 2 contains the crude drug amount;
5) concentrated solution 2 vacuum dryings get Radix Polygoni Multiflori glucoside crude extract powder, and described vacuum drying condition is: temperature is 55～70 ℃, and vacuum is 0.07～0.09Mpa, and it is 15～25g/g that dried powder contains the crude drug amount, and containing Radix Polygoni Multiflori glucoside is 50～70%.
This Radix Polygoni Multiflori glucoside crude extract can be that to contain the crude drug amount be 16-25g/g or contain the dried powder that Radix Polygoni Multiflori glucoside is 51-62%.
Powder useful formulations conventional method prepares oral preparation of Chinese traditional medicinal such as granule, capsule, tablet.
Concentrated solution useful formulations conventional method prepares oral liquid.Method is that adding preservative agent, correctives, accent pH value are 5.5～7.0, promptly gets oral liquid.
Adopt the Radix Polygoni Multiflori preparation of this prepared, oral capsule once carried out the pharmacological evaluation checking, had the effect of treatment fatty liver.Other peroral dosage forms are not because of having substantial process reform with capsule, so effective ingredient is not suffered a loss, effect should be suitable with oral capsule.
The specific embodiment
1. a plurality of factors that preparation method described in the technical scheme is related to are tested, with the elaboration of knowing clearly as the technical program.
1.1 the influence of pulverizing medicinal materials fineness to extracting
The influence of table 1 Radix Polygoni Multiflori pulverizing medicinal materials fineness to extracting
| Fineness | The filtration situation | Radix Polygoni Multiflori glucoside yield (%) |
| 8 14 20 | The good slightly difficulty of filtering | 3.50 3.52 3.51 |
1.2 Radix Polygoni Multiflori extraction process orthogonal test
Table 2 factor level table
| Concentration of alcohol (%) | Return time (min) | The ethanol multiple | |
| 1 2 3 | 30 50 70 | 30 45 60 | 6 8 10 |
Table 3 orthogonal experiments:
| Sequence number | A concentration | The B time | The C multiple | The D blank | Extractum yield (%) | Stilbene glucoside content (%) | Comprehensive grading |
| 1 2 3 4 5 6 7 8 9 | 1 1 1 2 2 2 3 3 3 | 1 2 3 1 2 3 1 2 3 | 1 2 3 2 3 1 3 1 2 | 1 2 3 3 1 2 2 3 1 | 8.0 8.0 7.0 11.8 12.4 12.2 11.8 12.8 13.5 | 10.8 18.4 26.3 16.4 17.9 15.2 16.6 17.7 17.5 | 9.4 13.2 16.65 14.1 15.15 13.7 14.2 15.25 15.5 |
| The extractum yield | K 1 | 22.98 | 31.59 | 33.00 | 33.90 | ||
| K 2 | 36.39 | 33.18 | 33.30 | 31.98 | |||
| K 3 | 38.10 | 32.70 | 31.20 | 31.59 | |||
| R 1 | 15.10 | 1.602 | 2.100 | 2.301 |
| Stilbene glucoside content | K 1 | 55.50 | 43.80 | 43.70 | 46.20 | ||
| K 2 | 49.50 | 54.00 | 52.30 | 50.20 | |||
| K 3 | 51.80 | 59.00 | 60.80 | 60.40 | |||
| R 2 | 6.000 | 15.20 | 17.10 | 14.20 | |||
| Comprehensive grading | K 1 | 39.25 | 37.70 | 38.35 | 40.05 | ||
| K 2 | 42.95 | 43.60 | 42.80 | 41.10 | |||
| K 3 | 44.95 | 45.85 | 46.00 | 46.00 | |||
| R 3 | 5.700 | 8.148 | 7.650 | 5.949 |
Experimental result: the stilbene glucoside assay of nine samples the results are shown in Table 3.
According to stilbene glucoside content in the yield of extract of medical material and the extractum, consider that according to combined factors such as range analysis and solvent cost determine to adopt 50% ethanol, 10 times, 8 times are extracted the backflow secondaries respectively, each time is 45min.
1.3 the purification of Radix Polygoni Multiflori glucoside (stilbene glucoside)
Table 4 different macroporous resin Radix Polygoni Multiflori glucoside residual concentration and than adsorbance situation
| Original liquid | HPD100 | HPD600 | D101 | DA201 | DM301 | D101 (spreading out) | |
| Weight resin (g) residual concentration (mg/mL) is than adsorbance (mg/mL) stripping liquid concentration (mg/mL) desorption efficiency (%) | - 3.186 - | 2.1584 0.236 34.16 1.328 90.08 | 2.0066 1.013 27.06 | 1.9895 1.016 27.26 | 1.9904 1.290 23.82 | 2.0560 0.438 33.4 1.160 84.4 | 2.1115 0.012 37.58 1.365 85.98 |
According to residual concentration, take all factors into consideration DM301, HPD than adsorbance and desorption efficiency etc.
100, D
101(spreading out) type resin all can be selected for use, with D
101(spreading out) type resin is excellent.
1.3.2 crude extract purification
Stilbene glucoside content in the table 4 purification thing
| Purity (%) | 0％ | 20％ | 40％ | 70％ |
| First second batch | - 6.03 | 4.98 0.48 | 58.97 60.46 | 13.28 23.61 |
Conclusion: select D
101Resin column, with 40%, 70% ethanol elution, stilbene glucoside content is the highest in the extract that the result obtains with 40% ethanol elution.So select D
101Resin column, the technology of doubly measuring 40% ethanol elution with 8-10 is suitable.
2. the application of the Radix Polygoni Multiflori in preparation
2.1 preparation solid preparation embodiment
With 1.2g/ml concentrated solution 10kg spray drying, get 650g Radix Polygoni Multiflori glucoside crude extract powder.
The 1 powder 500g that writes out a prescription, pregelatinized Starch 250g makes granule, granule.
Prescription 2 is got the granule in the prescription 1, and the cover capsule gets capsule.
Prescription 3 is got the granule 500g in the prescription 1, adds magnesium stearate 10g, and tabletting gets tablet.
2.2 preparation liquid preparation embodiment
Get the concentrated solution of 1.0g/ml, select different correctivess and different antiseptic, the preparation oral liquid, the result all meets the preparation requirement, sees Table 5.
Table 5 oral liquid formulations is observed table
| PH value | Stevioside | Essence | Potassium sorbate | The result |
| 6.9 5.8 6.4 | 0.1％ 0.2％ - | - - 0.1％ | 0.1％ 0.1％ 0.2％ | Character character up to specification character up to specification is up to specification |
3. Radix Polygoni Multiflori capsule (Radix Polygoni Multiflori glucoside crude extract) main pharmacodynamics result of study
3.1 CC14 is caused the influence of mice fatty liver
60 of ICR male mices, 30 ± 2g is divided into 6 groups at random: the high, medium and low dosage group of SW, model group, positive group (Essentiale N/Essentiale Forte N).Gastric infusion is 7 days continuously, and modeling in the 8th day is put to death after 24 hours and got liver.Get hepatic tissue 0.5g, high ferro-sulphuric acid development process is surveyed liver TC, the acetylacetone,2,4-pentanedione development process is surveyed liver TG, carries out the t check, the results are shown in Table 6; Remaining hepatic tissue 10% formaldehyde fixed is carried out pathology section examination.
Table 6SW causes the influence (X ± SD) of mice fatty liver to CCl4
| Grouping | Animal (only) | Dosage (mg/kg) | Liver TC (mg/g) | Liver TG (mg/g) |
| The high agent Essentiale N/Essentiale Forte N of agent SW among the low agent SW of normal model SW | 9 10 9 9 10 10 | -distilled water 500 1,000 2,000 76.0 | 6.15±0.99 12.16±3.48 △△△ 8.53±2.27 * 8.24±1.72 ** 8.82±1.61 * 7.32±1.47 ** | 32.97±17.84 91.70±36.91 △△△ 63.83±18.87 * 46.53±14.32 * 53.01±15.56 ** 58.03±20.40 * |
Compare with normal group: △ P＜0.05, △ △ P＜0.01, △ △ △ P＜0.001
Compare with model group:
*P＜0.05,
*P＜0.01,
* *P＜0.001 (down together)
As a result, liver TC, the TG of model group raise, and more all there were significant differences (P＜0.001) with normal group; And each dosage of SW all can reduce liver TC, TG to some extent, and relatively there were significant differences (P＜0.05) with model group.Show that SW has anti-CCl
4Cause the effect of mice fatty liver.
3.2 dexamethasone is caused the influence of mice fatty liver
60 of ICR female mices, 30 ± 2g divides 6 groups: the high, medium and low dosage group of SW, model group, positive group (Essentiale N/Essentiale Forte N), normal group, 10 every group at random.Every day, gastric infusion added modeling (removing normal group), continuous 8 days.Fasting was put to death after 12 hours.Get hepatic tissue 0.5g, the isopropyl alcohol extracting, high ferro-sulphuric acid development process is surveyed liver TC, the acetylacetone,2,4-pentanedione development process is surveyed liver TG, carries out the t check, the results are shown in Table 7; Remaining hepatic tissue 10% formaldehyde fixed is done pathological section.
Table 7SW causes the influence (X ± SD) of mice fatty liver to dexamethasone
| Grouping | Animal (only) | Dosage (mg/kg) | Liver TC (mg/g) | Liver TG (mg/g) |
| The high agent Essentiale N/Essentiale Forte N of agent SW among the low agent SW of normal model SW | 10 7 9 10 10 9 | -distilled water 500 1,000 2,000 76.0 | 9.41±1.90 15.23±1.89 △△△ 7.51±2.29 *** 6.97±2.06 *** 6.05±1.89 *** 10.15±2.66 *** | 84.95±22.52 144.99±30.99 △△ 91.33±23.22 ** 94.06±43.33 ** 63.01±20.19 *** 95.05±39.54 ** |
As a result, liver TC, the TG of model group raise, and more all there were significant differences (P＜0.001) with normal group; And high, medium and low three dosage of SW all can reduce liver TC, TG to some extent, with model group more all there were significant differences (P＜0.001-0.01).Show that SW has the effect that anti-dexamethasone causes the mice fatty liver.
3.3 high fat is caused the influence of mice fatty liver
60 of ICR male mices, 30 ± 2g is divided into 6 groups at random: the high, medium and low dosage group of SW, model group, positive group (simvastatin), normal group.Every day, gastric infusion added modeling (removing normal group), continuous 5 days.Fasting was put to death after 12 hours, got hepatic tissue 0.5g, the isopropyl alcohol extracting, and high ferro-sulphuric acid development process is surveyed liver TC, the acetylacetone,2,4-pentanedione development process is surveyed liver TG, carries out the t check, the results are shown in Table 8; Remaining hepatic tissue 10% formaldehyde fixed is done pathological section.
As a result, model group liver TC, TG all are significantly increased, with normal group relatively there were significant differences (P＜0.001-0.05); High, medium and low three dosage of SW all can reduce liver TC, TG to some extent, with model group relatively there were significant differences (P＜0.001-0.05).Show that SW has significantly anti-high fat mice fatty liver effect.
Table 8SW causes the influence (X ± SD) of mice fatty liver to high fat
| Grouping | Animal (only) | Dosage (mg/kg) | Liver TC (mg/g) | Liver TG (mg/g) |
| The high agent simvastatin of agent SW among the low agent SW of normal model SW | 10 9 10 10 9 9 | -distilled water 500 1,000 2,000 10 | 6.17±1.79 12.54±238 △△△ 9.93±2.94 10.35±1.84 8.11±3.30 ** 10.25±1.58 | 81.59±14.23 92.01±8.90△ 72.20±10.08 *** 77.36±12.50 ** 75.19±11.92 *** 69.39±12.45 *** |
3.4 ethanol is merged the influence that high fat causes the mice fatty liver
60 of ICR male mices, 30 ± 2g is divided into 6 groups at random: the high, medium and low dosage group of SW, model group, positive group (simvastatin), normal group.Every day, gastric infusion added modeling (removing normal group), continuous 2 weeks.Fasting was got blood after 12 hours, put to death and got liver.Survey liver TC, liver TG and blood TC, TG, carry out the t check, the results are shown in Table 9: remaining hepatic tissue 10% formaldehyde fixed, do pathological section.
As a result, liver TC, the TG of model group raise, and more all there were significant differences (P＜0.05) with normal group; And the high, medium and low dosage group of SW all can be in various degree reduction liver TC, TG, low dose group can reduce blood TC, relatively there were significant differences (P＜0.01) with model group.Show that SW has the effect that anti-ethanol merges high fat fatty liver.
Table 9SW merges the influence that high fat causes the mice fatty liver (X ± SD) to ethanol
| Group | Animal (only) | Dosage (mg/kg) | Liver TC (ng/g) | Liver TG (ng/g) | Blood TC (mmol/L) | Blood TG (mmol/L) |
| The low simvastatin of SW among the high SW of normal model SW | 10 9 9 9 9 9 | -distilled water 600 400 200 10 | 1.89±0.53 17.62±9.29 △△△ 7.30±4.61 * 10.53±5.96 6.66±2.38 ** 7.79±0.92 * | 3.72±1.11 22.03±9.50 △△△ 8.85±3.98 ** 16.72±5.60 16.91±9.71 14.41±4.31 * | 2.65±0.73 3.02±0.61 2.56±0.87 2.56±0.77 2.17±0.45 ** 2.20±0.51 ** | 0.93±0.28 0.78±0.20 0.86±0.34 0.99±0.35 1.11±0.40 0.78±0.28 |
3.5 ethanol is caused the influence of rat fat liver
72 of SD rats, 180 ± 20g, male and female half and half are divided into 6 groups at random: the high, medium and low dosage group of SW, model group, positive group (Essentiale N/Essentiale Forte N), normal group.Every day, gastric infusion added modeling (removing normal group), continuous 2 months.Fasting was got blood after 12 hours, put to death and got liver.Get hepatic tissue 0.5g, liver TC, TG, blood TC, TG are surveyed in the isopropyl alcohol extracting, and colorimetric method for determining liver T-SOD, MDA and blood T-SOD, MDA carry out the t check, the results are shown in Table 10,11; Remaining hepatic tissue 10% formaldehyde fixed is done pathological section.
Table 10SW causes the influence (X ± SD) of rat fat liver to ethanol
| Group | Animal (only) | Dosage (mg/kg) | Liver TC (mg/g) | Liver TG (mg/g) | Liver MDA (nmol/mgprot) | Liver SOD (U/mgprot) |
| The high Essentiale N/Essentiale Forte N of SW among the low SW of normal model SW | 9 8 9 10 9 8 | Distilled water 200 400 600 76.0 | 3.96±1.28 8.47±1.96 △△△ 4.99±1.23 ** 6.89±0.84 5.96±0.89 ** 2.81±1.27 *** | 9.39±3.00 16.65±6.18 7.47±2.27 ** 9.38±2.72 * 10.18±3.77 12.05±3.75 | 1.151±0.22 2.63±0.71 △△ 1.43±0.25 ** 1.33±0.16 *** 1.61±0.32 ** 1.63±0.31 ** | 28.07±5.75 26.12±3.55 18.35±3.75 19.48±4.28 23.29±4.54 19.33±4.74 |
Table 11SW causes the influence (X ± SD) of rat fat hepatic blood index to ethanol
| Group | Animal (only) | Dosage (mg/kg) | Blood TC (mmol/l) | Blood TG (mmol/l) | Blood MDA (U/mgprot) | Blood SOD (nmol/mgprot) |
| The high Essentiale N/Essentiale Forte N of SW among the low SW of normal model SW | 9 8 9 10 9 8 | Distilled water 200 400 600 76.0 | 0.949±0.138 1.22±0.26 △ 1.55±0.43 1.88±0.44 ** 1.65±0.32 ** 1.50±0.42 | 0.689±0.21 0.667±0.19 0.751±0.193 0.935±0.31 * 0.571±0.10 0.787±0.26 | 10.97±0.88 12.80±1.51 △ 11.84±1.29 11.59±0.73 11.31±0.94 * 11.62±0.81 | 353.67±89.03 442.14±75.01 △ 442.41±80.11 430.0±62.72 493.6±75.54 381.2±165.70 |
Table 11 result shows, liver TC, TG and the MDA of model group all raise, SOD then descends, with normal group comparison liver TC, MDA significant difference (P＜0.001-0.01): and high, medium and low three dosage of SW is arranged, liver TC, TG and blood MDA all there are in various degree reduction, significant difference (P＜0.001-0.05) are relatively arranged with model group.
3.6 acid causes the influence of rat fat liver to diethyldithiocarbamate
Get 60 of SD rats, male and female half and half, body weight are 280 ± 30g, are divided into 6 groups at random: the high, medium and low dosage group of SW, model group, positive group (Essentiale N/Essentiale Forte N), normal group.Every day, gastric infusion added modeling (removing normal group), continuous 20 days.Fasting 12 hours is put to death and is got liver.Get hepatic tissue 0.5g, the isopropyl alcohol extracting, high ferro-sulphuric acid development process is surveyed liver TC, the acetylacetone,2,4-pentanedione development process is surveyed liver TG, surveys GPT and TG in the blood, carries out the t check, the results are shown in Table 12: remaining hepatic tissue 10% formaldehyde fixed, do pathological section.
Table 12SW causes the influence (X ± SD) of SD rat fat liver to ethionine
| Group | Animal (only) | Dosage (mg/kg) | Liver TC (ng/g) | Liver TG (ng/g) | Blood TC (mmol/L) | Blood GTP (karmen) |
| The high Essentiale N/Essentiale Forte N of SW among the low SW of normal model SW | 10 9 10 10 9 10 | -distilled water 500 1,000 2,000 76 | 5.56±0.85 5.66±1.85 5.02±0.89 4.82±0.84 4.55±0.78 5.371±1.60 | 14.12±2.37 13.86±4.71 18.67±6.57 15.75±5.32 17.99±6.69 12.96±4.40 | 4.11±1.06 3.41±0.67 4.40±0.90 4.76±0.64 4.43±1.41 4.93±0.50 | 61.69±8.38 79.09±5.42 △△△ 65.35±7.06 *** 56.13±8.67 *** 60.07±10.08 *** 59.95±6.13 *** |
As a result, the blood GTP of model group raises, and more all there were significant differences (P＜0.001) with normal group; And each dosage group of SW all can reduce blood GTP, with model group significance (P＜0.001) is arranged relatively.Show that SW has the effect that certain anti-ethionine causes the fat fatty liver.
Claims (9)
1. Radix Polygoni Multiflori glucoside crude extract, make by following steps:
(1) Radix Polygoni Multiflori medicinal material coarse powder adds the alcohol reflux secondary, filters, and gets filtrate;
(2) filtrate recycling ethanol is not to there being the alcohol flavor, and concentrate concentrated solution 1;
(3) concentrated solution 1 adopts macroporous resin to separate, and obtains eluent;
(4) eluent reclaims ethanol to there not being the alcohol flavor, and concentrate concentrated solution 2;
(5) concentrated solution 2 vacuum dryings get Radix Polygoni Multiflori glucoside crude extract powder.
2. Radix Polygoni Multiflori glucoside crude extract as claimed in claim 1 is characterized in that Radix Polygoni Multiflori medical material is through being ground into 8～20 order powder-processed in the step (1).
3. Radix Polygoni Multiflori glucoside crude extract as claimed in claim 1 is characterized in that the method that adds alcohol reflux described in the step (1) is: add 6-10 for the first time and doubly measured the 30-70% alcohol reflux 30-60 minute, filter; For the second time add 6-8 again and doubly measured the 30-70% alcohol reflux 30-60 minute, merge backflow, filter, get filtrate.
4. Radix Polygoni Multiflori glucoside crude extract as claimed in claim 1, it is characterized in that the described concentration process of step (2) is a concentrating under reduced pressure, 55～70 ℃ of thickening temperatures, vacuum are 0.07～0.09Mpa, and it is that 0.25～0.50g/ml or relative density are 1.01～1.06 that concentrated solution 1 contains the crude drug amount.
5. Radix Polygoni Multiflori glucoside crude extract as claimed in claim 1 is characterized in that the described macroporous resin of step (3) is D
101, DM
301, HPD
100One of, eluant is 20%～70% ethanol, consumption is 8-10 times.
6. Radix Polygoni Multiflori glucoside crude extract as claimed in claim 1, it is characterized in that described recovery ethanol of step (4) and concentration process are decompression and carry out, 55～70 ℃ of temperature, vacuum are 0.07～0.09Mpa, and it is that 1.5～2.5g/ml or relative density are 1.05～1.25 that concentrated solution 2 contains the crude drug amount.
7. the described Radix Polygoni Multiflori glucoside crude extract of claim 1, it is characterized in that the described vacuum drying condition of step (5) is that 55～70 ℃ of temperature, vacuum are 0.07～0.09Mpa, it is 15～25g/g that Radix Polygoni Multiflori glucoside crude extract powder contains the crude drug amount, and containing Radix Polygoni Multiflori glucoside is 50～70%.
8. the application of Radix Polygoni Multiflori glucoside crude extract as claimed in claim 1 in preparation treatment fatty liver medicine.
9. application as claimed in claim 8 is characterized in that described Radix Polygoni Multiflori glucoside crude extract makes capsule or granule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100295663A CN100377723C (en) | 2004-03-24 | 2004-03-24 | Application of fleece flower root in preparing medicine for treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100295663A CN100377723C (en) | 2004-03-24 | 2004-03-24 | Application of fleece flower root in preparing medicine for treating fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1672719A CN1672719A (en) | 2005-09-28 |
| CN100377723C true CN100377723C (en) | 2008-04-02 |
Family
ID=35045661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100295663A Expired - Fee Related CN100377723C (en) | 2004-03-24 | 2004-03-24 | Application of fleece flower root in preparing medicine for treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100377723C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102641344A (en) * | 2011-02-16 | 2012-08-22 | 浙江中医药大学 | Application of tuber fleeceflower root glycoside in treatment of hyperlipidemia |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102485240A (en) * | 2010-12-03 | 2012-06-06 | 贵州大学 | Fleece-flower root particulate agent and its preparation method |
| CN102614204A (en) * | 2012-03-12 | 2012-08-01 | 中国人民解放军第四军医大学 | New application of stilbene glucoside to hangover alleviation |
| CN102697871B (en) * | 2012-06-06 | 2014-04-16 | 广西中医药大学 | Chinese herbal preparation with liver protecting and enzyme reducing effects and production method of same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060481C (en) * | 1998-10-14 | 2001-01-10 | 北京中医药大学 | Method for extraction and separation of active component of traditional Chinese medicine fleece flower root |
| CN1370552A (en) * | 2001-02-23 | 2002-09-25 | 田维熙 | Fatty acid synthetase inhibitor and its prepn and application |
| CN1114419C (en) * | 2000-01-22 | 2003-07-16 | 广东医学院医药科技开发中心 | Application of Radix Polygoni Multiflori and its extract in preventing and treating osteoporosis |
| CN1456291A (en) * | 2003-04-10 | 2003-11-19 | 毛友昌 | Fleece-flower root capsule for lengthening life and preparing method thereof |
-
2004
- 2004-03-24 CN CNB2004100295663A patent/CN100377723C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060481C (en) * | 1998-10-14 | 2001-01-10 | 北京中医药大学 | Method for extraction and separation of active component of traditional Chinese medicine fleece flower root |
| CN1114419C (en) * | 2000-01-22 | 2003-07-16 | 广东医学院医药科技开发中心 | Application of Radix Polygoni Multiflori and its extract in preventing and treating osteoporosis |
| CN1370552A (en) * | 2001-02-23 | 2002-09-25 | 田维熙 | Fatty acid synthetase inhibitor and its prepn and application |
| CN1456291A (en) * | 2003-04-10 | 2003-11-19 | 毛友昌 | Fleece-flower root capsule for lengthening life and preparing method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 国家中成药标准汇编 内科 气血津液 分册. 国家药品监督管理局，478-488，国家药品监督管理局. 2002 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102641344A (en) * | 2011-02-16 | 2012-08-22 | 浙江中医药大学 | Application of tuber fleeceflower root glycoside in treatment of hyperlipidemia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1672719A (en) | 2005-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101396544B (en) | Traditional Chinese medicine composition capable of ventilating the lung and relieving asthma and preparation method thereof | |
| CN104856968B (en) | A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof | |
| CN102988827A (en) | Dendrobium officinale granula | |
| CN101596295B (en) | Medicinal composition for treating gout and preparation process thereof | |
| CN101396545A (en) | Traditional Chinese medicine composition for treating disharmony between the liver and the spleen and preparation method and quality control method thereof | |
| CN104138526B (en) | A kind of root of three-nerved spicebush iron sheet ginseng granules agent | |
| CN101810686A (en) | Compatible composition for treating rheumatoid arthritis and preparation method thereof | |
| CN102305839A (en) | Detection method of traditional Chinese medicine composition for freeing lung and relieving asthma | |
| CN100377723C (en) | Application of fleece flower root in preparing medicine for treating fatty liver | |
| CN105125620A (en) | Caesalpinia decapetala extract and preparing method and medical application thereof | |
| CN108434399A (en) | A kind of Chinese medicine composition and preparation method of anti-curing oncoma | |
| CN101347605B (en) | Chinese medicinal composition for treating gout and preparation method and application thereof | |
| CN100355448C (en) | Chinese traditional medicine compound preparation for preventing and curing alcoholic intestinal tract and liver injury | |
| CN101129974A (en) | Traditional Chinese medicine composition for treating hepatopathy and method of preparing the same | |
| CN102805836B (en) | A kind of Chinese medicine composition for the treatment of primary hepatocarcinoma and preparation method thereof | |
| CN102139072B (en) | Chinese medicinal preparation for treating gynecological inflammation | |
| CN101375983B (en) | Chinese medicinal composition for treating dysmenorrhea and preparation method thereof | |
| CN102579869A (en) | Preparation method of traditional Tibetan medicine composition for treating liver diseases | |
| CN102349956B (en) | Compound extract for moisturizeing pathogenic dryness and relieving itching and preparation thereof | |
| CN104906243A (en) | Traditional Chinese medicine compound with liver protection function | |
| CN101804083A (en) | Application of pollen pini and extract thereof in treating inflammatory bowel disease and method for preparing extract | |
| CN105477213A (en) | Traditional Chinese medicine composition for reducing blood fat and preparing method thereof | |
| CN100502913C (en) | Vitex trifolia extract and its preparing method and use | |
| CN101167798B (en) | Method for preparing active parts in scutellaria decoction for treating ulcer colonitis and uses | |
| CN1985909A (en) | Medicine for hyperlipemia and its production process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080402 Termination date: 20200324 |